The Technical Analyst
Select Language :
Dynavax Technologies Corp [DVAX]

Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic

Dynavax Technologies Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Dynavax Technologies Corp is listed at the  Exchange

0.00% $12.41

America/New_York / 28 mar 2024 @ 16:00


Dynavax Technologies Corp: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 1 620.93 mill
EPS: -0.0500
P/E: -248.20
Earnings Date: Apr 29, 2024
SharesOutstanding: 130.62 mill
Avg Daily Volume: 2.000 mill
RATING 2024-03-28
A
Buy
RATINGS
Rating CashFlow: Buy
Return On Equity: Neutral
Return On Asset: Buy
DE: Buy
P/E: Strong Buy
Price To Book: Neutral
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -248.20 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-5.20x
Company: PE -248.20 | industry: PE 47.78
DISCOUNTED CASH FLOW VALUE
N/A
N/A
Expected Trading Range (DAY)

$ 12.06 - 12.76

( +/- 2.84%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-16 Burgess Justin Buy 20 000 Stock Options (Right to Buy)
2024-03-01 Burgess Justin Buy 2 767 Common Stock
2024-03-01 Burgess Justin Buy 4 334 Common Stock
2024-03-01 Burgess Justin Sell 7 101 Common Stock
2024-03-01 Burgess Justin Sell 4 334 Stock Options (Right to Buy)
INSIDER POWER
-19.45
Last 100 transactions
Buy: 1 161 830 | Sell: 2 152 314

Forecast: 16:00 - $12.42

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $12.42
Forecast 2: 16:00 - $12.42
Forecast 3: 16:00 - $12.42
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $12.41 (0.00% )
Volume 1.332 mill
Avg. Vol. 2.000 mill
% of Avg. Vol 66.62 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Dynavax Technologies Corp

Last 12 Months

Last 12 months chart data with high, low, open and close for Dynavax Technologies Corp

RSI

Intraday RSI14 chart for Dynavax Technologies Corp

Last 10 Buy & Sell Signals For DVAX

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$12.92N/AActive
Profile picture for
            Dynavax Technologies Corp

DVAX

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; agreement with Serum Institute of India Pvt. Ltd.; and sublicense agreement with Merck, Sharp & Dohme Corp. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California.

Last 10 Buy Signals

Date Signal @
KCSUSDMar 29 - 04:24$11.87
FTNUSDMar 29 - 04:141.819
ORAIUSDMar 29 - 04:0814.59
IONUSDMar 29 - 04:08452.00
MXUSDMar 29 - 04:07$4.21
RETHUSDMar 29 - 04:043 905.62
ABTUSDMar 29 - 04:041.978
XU100.ISMar 29 - 04:03PTS9 101.28
DYDXUSDMar 29 - 04:003.39
^KLSEMar 29 - 03:46PTS1 536.68

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.